406 related articles for article (PubMed ID: 31478086)
1. Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Ozawa T; Hashiguchi Y; Yagi T; Fukushima Y; Shimada R; Hayama T; Tsuchiya T; Nozawa K; Iinuma H; Ishihara S; Matsuda K
Int J Colorectal Dis; 2019 Oct; 34(10):1731-1739. PubMed ID: 31478086
[TBL] [Abstract][Full Text] [Related]
2. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
Htoo PT; Stürmer T; Jonsson-Funk M; Pate V; Simpson RJ; Lund JL
Epidemiology; 2019 Nov; 30(6):867-875. PubMed ID: 31348009
[TBL] [Abstract][Full Text] [Related]
3. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
6. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer.
Maloney LT; Latour E; Chen Y; Rice D; Grossblatt-Wait A; Nabavizadeh N; Thomas CR; Young KH; Walker JM; Holland J; Grossberg AJ
Cancer Biol Ther; 2022 Dec; 23(1):1-8. PubMed ID: 36201632
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
9. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
[TBL] [Abstract][Full Text] [Related]
10. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
11. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
12. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
15. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
[TBL] [Abstract][Full Text] [Related]
18. Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative.
Brasky TM; Flores KF; Larson JC; Newton AM; Shadyab AH; Watanabe JH; Lane DS; Thomson CA; LaCroix AZ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):1029-1032. PubMed ID: 33627382
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
[TBL] [Abstract][Full Text] [Related]
20. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Miao L; Chen W; Zhou L; Wan H; Gao B; Feng Y
Sci Rep; 2016 Feb; 6():21359. PubMed ID: 26883083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]